GlassScriptPhysician profile
Jessica L Levy
NPI 1790253821
$5,573.27
in general payments reported to CMS, 2019-2025
31 companies · $1,595 in 2025
The $1,595 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,111 · 2023: $1,500 · 2024: $1,366 · 2025: $1,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,382 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,381.92 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $730.82 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $555.19 | 2022-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $478.37 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Sumitomo Pharma America, INC. | $450.06 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $445.15 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $361.21 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.41 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $311.93 | 2022-2024 | Xarelto |
| Pfizer INC. | $251.18 | 2022-2025 | |
| Novo Nordisk INC | $223.54 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Radius Health, INC. | $199.79 | 2022-2025 | Tymlos |
| Exact Sciences Corporation | $142.63 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $136.11 | 2022-2023 | |
| Astellas Pharma US INC | $133.88 | 2023-2025 | Veozah |
| Abbvie INC. | $122.19 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $103.38 | 2022-2025 | Orthovisc, Monovisc |
| Sunovion Pharmaceuticals INC. | $93.85 | 2022 | |
| Ardelyx, INC. | $86.67 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.92 | 2023-2025 | Xifaxan, Trulance |
| Idorsia Pharmaceuticals US INC | $48.52 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $47.22 | 2023-2024 | Rexulti |
| Abbott Laboratories | $37.15 | 2024-2025 | Freestyle Libre |
| Dexcom, INC. | $35.05 | 2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $32.54 | 2024-2025 | Nexletol |
| Eisai INC. | $26.19 | 2025 | |
| Heartflow, INC. | $25.47 | 2025 | |
| Amarin Pharma, INC. | $22.36 | 2022 | |
| Amneal Pharmaceuticals LLC | $18.68 | 2022 | |
| Currax Pharmaceuticals LLC | $17.66 | 2022 | |
| Phadia US INC. | $16.13 | 2025 | Immunocap |
| Merck Sharp & Dohme LLC | $13.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.